MARKER THERAPEUTICS INC (MRKR) Fundamental Analysis & Valuation

NASDAQ:MRKR • US57055L2060

Current stock price

1.42 USD
-0.03 (-2.07%)
Last:

This MRKR fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. MRKR Profitability Analysis

1.1 Basic Checks

  • In the past year MRKR has reported negative net income.
  • In the past year MRKR has reported a negative cash flow from operations.
  • In the past 5 years MRKR always reported negative net income.
  • In the past 5 years MRKR always reported negative operating cash flow.
MRKR Yearly Net Income VS EBIT VS OCF VS FCFMRKR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -50M -100M

1.2 Ratios

  • MRKR has a Return On Assets of -63.78%. This is in the lower half of the industry: MRKR underperforms 62.14% of its industry peers.
  • MRKR has a Return On Equity (-72.42%) which is in line with its industry peers.
Industry RankSector Rank
ROA -63.78%
ROE -72.42%
ROIC N/A
ROA(3y)-53.53%
ROA(5y)-61.8%
ROE(3y)-62.95%
ROE(5y)-87.35%
ROIC(3y)N/A
ROIC(5y)N/A
MRKR Yearly ROA, ROE, ROICMRKR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -50 -100 -150 -200 -250

1.3 Margins

  • MRKR does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MRKR Yearly Profit, Operating, Gross MarginsMRKR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -20K -40K -60K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. MRKR Health Analysis

2.1 Basic Checks

  • The number of shares outstanding for MRKR has been increased compared to 1 year ago.
  • The number of shares outstanding for MRKR has been increased compared to 5 years ago.
  • MRKR has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
MRKR Yearly Shares OutstandingMRKR Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5M 10M 15M
MRKR Yearly Total Debt VS Total AssetsMRKR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M

2.2 Solvency

  • MRKR has an Altman-Z score of -28.24. This is a bad value and indicates that MRKR is not financially healthy and even has some risk of bankruptcy.
  • The Altman-Z score of MRKR (-28.24) is worse than 88.35% of its industry peers.
  • MRKR has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -28.24
ROIC/WACCN/A
WACCN/A
MRKR Yearly LT Debt VS Equity VS FCFMRKR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20M -20M 40M

2.3 Liquidity

  • MRKR has a Current Ratio of 8.39. This indicates that MRKR is financially healthy and has no problem in meeting its short term obligations.
  • MRKR's Current ratio of 8.39 is fine compared to the rest of the industry. MRKR outperforms 73.20% of its industry peers.
  • MRKR has a Quick Ratio of 8.39. This indicates that MRKR is financially healthy and has no problem in meeting its short term obligations.
  • MRKR has a Quick ratio of 8.39. This is in the better half of the industry: MRKR outperforms 73.40% of its industry peers.
Industry RankSector Rank
Current Ratio 8.39
Quick Ratio 8.39
MRKR Yearly Current Assets VS Current LiabilitesMRKR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. MRKR Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 28.33% over the past year.
  • The Revenue for MRKR has decreased by -46.19% in the past year. This is quite bad
  • Measured over the past years, MRKR shows a very strong growth in Revenue. The Revenue has been growing by 49.81% on average per year.
EPS 1Y (TTM)28.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%78.57%
Revenue 1Y (TTM)-46.19%
Revenue growth 3Y-26.71%
Revenue growth 5Y49.81%
Sales Q2Q%-50.98%

3.2 Future

  • Based on estimates for the next years, MRKR will show a very strong growth in Earnings Per Share. The EPS will grow by 39.58% on average per year.
  • Based on estimates for the next years, MRKR will show a very strong growth in Revenue. The Revenue will grow by 152.30% on average per year.
EPS Next Y-17.81%
EPS Next 2Y-9.81%
EPS Next 3Y37.1%
EPS Next 5Y39.58%
Revenue Next Year-13.06%
Revenue Next 2Y200.15%
Revenue Next 3Y241.16%
Revenue Next 5Y152.3%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
MRKR Yearly Revenue VS EstimatesMRKR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M 400M
MRKR Yearly EPS VS EstimatesMRKR Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -20 -40 -60 -80

More info and screens

Find the best growth stocksShow best growing peers

1

4. MRKR Valuation Analysis

4.1 Price/Earnings Ratio

  • MRKR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year MRKR is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MRKR Price Earnings VS Forward Price EarningsMRKR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MRKR Per share dataMRKR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 -1

4.3 Compensation for Growth

  • A more expensive valuation may be justified as MRKR's earnings are expected to grow with 37.10% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-9.81%
EPS Next 3Y37.1%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. MRKR Dividend Analysis

5.1 Amount

  • No dividends for MRKR!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

MRKR Fundamentals: All Metrics, Ratios and Statistics

MARKER THERAPEUTICS INC

NASDAQ:MRKR (4/28/2026, 6:44:00 PM)

1.42

-0.03 (-2.07%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-18
Earnings (Next)05-13
Inst Owners24.25%
Inst Owner Change-0.9%
Ins Owners1.64%
Ins Owner Change0%
Market Cap23.67M
Revenue(TTM)3.55M
Net Income(TTM)-12.16M
Analysts82.22
Price Target8.02 (464.79%)
Short Float %1.21%
Short Ratio1.42
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)64.5%
Min EPS beat(2)55.14%
Max EPS beat(2)73.86%
EPS beat(4)4
Avg EPS beat(4)46.92%
Min EPS beat(4)28.04%
Max EPS beat(4)73.86%
EPS beat(8)6
Avg EPS beat(8)21.59%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)62.95%
Min Revenue beat(2)58.7%
Max Revenue beat(2)67.2%
Revenue beat(4)3
Avg Revenue beat(4)27.77%
Min Revenue beat(4)-31.57%
Max Revenue beat(4)67.2%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-12.83%
PT rev (3m)-12.83%
EPS NQ rev (1m)0%
EPS NQ rev (3m)16.67%
EPS NY rev (1m)31.02%
EPS NY rev (3m)31.02%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)13.67%
Revenue NY rev (1m)-0.18%
Revenue NY rev (3m)-0.18%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 6.67
P/FCF N/A
P/OCF N/A
P/B 1.41
P/tB 1.41
EV/EBITDA N/A
EPS(TTM)-0.86
EYN/A
EPS(NY)-1.01
Fwd EYN/A
FCF(TTM)-0.72
FCFYN/A
OCF(TTM)-0.72
OCFYN/A
SpS0.21
BVpS1.01
TBVpS1.01
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -63.78%
ROE -72.42%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-53.53%
ROA(5y)-61.8%
ROE(3y)-62.95%
ROE(5y)-87.35%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.19
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 8.39
Quick Ratio 8.39
Altman-Z -28.24
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)28.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%78.57%
EPS Next Y-17.81%
EPS Next 2Y-9.81%
EPS Next 3Y37.1%
EPS Next 5Y39.58%
Revenue 1Y (TTM)-46.19%
Revenue growth 3Y-26.71%
Revenue growth 5Y49.81%
Sales Q2Q%-50.98%
Revenue Next Year-13.06%
Revenue Next 2Y200.15%
Revenue Next 3Y241.16%
Revenue Next 5Y152.3%
EBIT growth 1Y-11.84%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-3.3%
EBIT Next 3Y35.91%
EBIT Next 5Y42.33%
FCF growth 1Y-10.12%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-10.12%
OCF growth 3YN/A
OCF growth 5YN/A

MARKER THERAPEUTICS INC / MRKR Fundamental Analysis FAQ

What is the fundamental rating for MRKR stock?

ChartMill assigns a fundamental rating of 3 / 10 to MRKR.


What is the valuation status of MARKER THERAPEUTICS INC (MRKR) stock?

ChartMill assigns a valuation rating of 1 / 10 to MARKER THERAPEUTICS INC (MRKR). This can be considered as Overvalued.


What is the profitability of MRKR stock?

MARKER THERAPEUTICS INC (MRKR) has a profitability rating of 0 / 10.


What is the expected EPS growth for MARKER THERAPEUTICS INC (MRKR) stock?

The Earnings per Share (EPS) of MARKER THERAPEUTICS INC (MRKR) is expected to decline by -17.81% in the next year.